Table 1 Incidence of ErbB family kinase domain duplications (KDDs) across tumor types.

From: Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

(a) Incidence of different ErbB-KDDs across 237,701 solid tumor and hematological samples from the Foundation Medicine (FMI) database

Tumor type

EGFR

ERBB2

ERBB3

ERBB4

Sample size

Glioma

222

1

4

0

9381

NSCLC

70

18

11

10

48,699

GI

40

44

3

2

11,822

Melanoma

2

0

5

0

6837

Prostate

4

1

1

4

8203

Bladder

6

3

2

2

4886

GYN

10

40

34

16

26,873

Breast

27

52

13

7

24,467

HNC

2

7

1

0

5380

(b) Incidence of different ErbB-KDDs across 40,165 solid tumor and hematological samples from Memorial Sloan Kettering Cancer Center (MSKCC) IMPACT database

Tumor type

EGFR

ERBB2

Sample size

Glioma

10

0

1735

Breast

1

2

5614

NSCLC

3

1

5986

Bladder

0

1

1266

GYN

0

1

1600

  1. NSCLC: non-small cell lung cancer; GI: gastrointestinal cancer; GYN: gynecological cancer; HNC: head and neck cancer.
Back to article page